Scienza e Tecnologia
Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio
Discover which therapies are expected to grab the major geographic atrophy market share @
Geographic atrophy is a severe form of age-related macular degeneration (AMD). Macular degeneration, commonly known as age-related macular degeneration, is a medical disorder that causes blurred or no vision in the center of the visual field. There are two types of macular degeneration: "dry" and "wet." Geographic atrophy is a blinding, progressive, irreversible disease that affects both eyes. Nearly two-thirds of all occurrences of geographic atrophy are observed in adults aged 80 and up. Geographic atrophy is responsible for 20% of all cases of legal blindness in the United States and 26% of cases in the United Kingdom .
Geographic atrophy is distinguished by one or more noticeable dark patches on the retina, as well as corresponding areas of impaired vision or "blind spots." These black patches signify the demise of many retinal cell types, including light-sensitive photoreceptors. Geographic atrophy is evaluated with a visual acuity test. Unfortunately, visual acuity alone does not adequately convey the functional impact of Geographic atrophy, such as loss of reading skills, emphasizing the need for enhanced testing.
As per DelveInsight estimates, the total diagnosed cases of geographic atrophy by age distribution were highest in the 75–79 years of age group in the 7MM in 2021.
The geographic atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
In February 2023 , the US FDA authorized for the treatment of geographic atrophy secondary to age-related macular degeneration. SYFOVRE was the first and only FDA-approved therapy for geographic atrophy. SYFOVRE was approved based on favorable findings from the Phase III OAKS and DERBY studies at 24 months in a large and representative patient group. The AREDS study looked at the role of a specific supplementation formula (80 mg zinc oxide, 2 mg cupric oxide, 15 mg -carotene, 500 mg vitamin Cand 400 IU vitamin E) in the various stages of d-AMD. This formula supplementation was not shown to be useful in slowing the growth rate of geographic atrophy, most likely due to the study's limited sample size of geographic atrophy patients.
High dosages of antioxidant vitamins (vitamins C, E, and beta-carotene) and zinc supplements have been shown to decrease the course of d-AMD. A high dietary folate consumption also appears to minimize the likelihood of development to geographic atrophy, albeit this impact may be influenced by the genetic profile associated with C3R102G. Neuroprotection is regarded to be critical in AMD. Furthermore, photoreceptor cell degeneration and death are the cause of visual loss in several retinal illnesses, including retinitis pigmentosa, retinal detachment, and geographic atrophy. A useful way of neuroprotection could be good therapy for geographic atrophy.
To know more about geographic atrophy treatment, visit @
Learn more about the FDA-approved drugs for geographic atrophy @
The dynamics of the geographic atrophy market are expected to change in the coming years. Payers' willingness to pay is assumed to be strong since the creates a high unmet demand and the possibility of avoiding progression to wet AMD, which is associated with high treatment costs. Moreover, due to the , clinical outcome requirements may be minimal; hence, sham or placebo-controlled clinical trials may suffice for initial entrants. Furthermore, the with improved efficacy and a further are expected to drive the growth of the geographic atrophy market in the 7MM.
However, several factors are impeding the growth of the geographic atrophy market. There is a
, which may impede the evolution of medicines and their ability to demonstrate clinical benefits. Several
have failed to slow the course of geographic atrophy. Furthermore, the geographic atrophy market growth may be offset by
, ,
, and a . In addition, the
about the disease may also impact the geographic atrophy market growth.
Discover more about geographic atrophy drugs in development @
report delivers an in-depth understanding of the disease, historical and forecasted geographic atrophy epidemiology in the 7MM, i.e., the United States , EU5 ( Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key geographic atrophy companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key age-related macular degeneration companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key age-related macular degeneration companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865705.html